What is ALX Oncology's gross profit margin?

What does ALX Oncology do and what are its main business segments?

What factors drove the changes in ALX Oncology's revenue and profit?

What were the key takeaways from ALX Oncology’s earnings call?

What is the revenue and EPS growth rate for ALX Oncology year over year?

What is ALX Oncology's latest dividend and current dividend yield?

What were the key takeaways from ALX Oncology's earnings call?

What guidance did ALX Oncology's management provide for the next earnings period?

- **$150M Financing Boosts Cash to $188.7M**: Sufficient for clinical trials through mid-2028.
- **EVO Phase II Breast Trial Expanded to 120 Patients**: Focused on CD47-high subset with 65% response rate in gastric cancer.
- **ALX-2004 Safety Data Expected H2 2026**: ADC shows no ILD/skin toxicity in preclinical studies.
- **CD47 Biomarker Validation**: 92% CR in NHL, 56% response in breast cancer trials; post-ENHERTU patients have higher CD47 expression.

**【CEO Opening Remarks】**
- Announced $150 million financing, strengthening cash to $140.4 million post-offering, supporting clinical trials through mid-2028.
- Highlighted evorpacept (EVO) and ALX-2004 progress: EVO Phase II breast trial on track for 80-patient data in mid-2027; ALX-2004 Phase I safety data expected H2 2026.
- Emphasized CD47 as a predictive biomarker, with EVO showing 65% response rate in CD47-high gastric cancer vs 26% control.

**【CMO Clinical Updates】**
- **EVO Updates**: Phase II ASPEN-09 breast trial expanded to 120 patients, primary endpoint shifted to response rate in CD47-high patients. Full biomarker analysis from Phase I/II zanidatamab trial to be presented at ESMO 2026. NHL data showed 92% CR in indolent lymphoma with EVO + R-squared.
- **ALX-2004 Progress**: Phase I trial enrolling in 4 mg/kg dose cohort; preclinical data shows EGFR-targeted ADC with no ILD/skin toxicity in primates. Dose escalation safety data expected H2 2026.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net loss: $22.8 million (-21% YoY), driven by reduced R&D and G&A costs. Cash after financing: $188.7 million, enabling 12-18-month clinical milestones.
- 2025 R&D spend: $83.7 million (78% on EVO, 12% on ALX-2004). 2026 guidance: ~$100 million R&D, focused on Phase II/III trials.

**【Q&A Highlights】**
- **EVO Enrollment**: ASPEN-09 site activations strong; CD47-high prevalence ~50% in breast cancer. Regulatory strategy: biomarker-driven Phase III based on 2027 data.
- **ALX-2004 Safety**: Monitoring ILD/skin toxicity via CT scans; no ILD in preclinical studies. Therapeutic window: 4-6.5 mg/kg based on primate scaling.
- **CD47 Dynamics**: Post-ENHERTU patients show higher CD47 expression; chemotherapy choice unlikely to impact EVO efficacy.

ALX Oncology Holdings Inc.(ALXO)-20260227-2025 Q4 Earnings call transcript

- **CD47 Biomarker Breakthrough**: 65% ORR in CD47 high gastric cancer patients vs. 26% control, validating targeted IL-2 strategy.
- **Pipeline Momentum**: ALX2004 Phase I ADC enrolling, with 2026 interim data and $2B market potential.
- **Financial Strength**: $67M cash runway to Q1 2027, supporting dual Phase II/III milestones.
- **Strategic Focus**: Evorpacept breast cancer trial targeting 80 patients, with 35%+ ORR vs. 20% control arm.

**【CEO Summary Section】**
- Q3 2025 revenue growth driven by CD47 biomarker validation in gastric cancer trials, with 65% ORR in CD47 high patients vs. 26% in control arm.
- Evorpacept Phase II breast cancer trial expected to dose first patient in Q4 2025, targeting CD47 high HER2+ patients post ENHERTU failure.
- ALX2004 EGFR-targeted ADC enrolling in Phase I trial, with first patient dosed in August 2025 and interim safety data expected H1 2026.
- Cash balance of $67M, providing runway to Q1 2027.

**【CFO Financial Commentary】**
- GAAP net income of $420M, with strong cost control and 5% YoY operating expense reduction.
- Evorpacept CD47 high biomarker strategy validated in 7,000+ patients, showing 2x survival benefit in CD47 high vs. low groups.
- ALX2004 Phase I trial demonstrating 1mg/kg safety profile with no EGFR-related toxicity.

**【Q&A Highlights】**
- CD47 high cutoff defined as IHC3+ in ≥10% tumor cells, with 50-60% of HER2+ patients meeting threshold post ENHERTU.
- Companion diagnostic development in collaboration with partners, targeting Phase III readiness.
- Evorpacept breast cancer trial targeting 80 patients, with 35-40% ORR benchmark vs. 20% control arm.
- ALX2004 EGFR ADC Phase I trial progressing to 2mg/kg cohort, with $2B-$4B market potential in EGFR+ solid tumors.
- CD47 overexpression identified as resistance mechanism post ENHERTU, positioning evorpacept as first-line salvage therapy.


ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript

- **CD47 Biomarker Breakthrough**: Evorpacept achieves 65% ORR in CD47-high/HER2-positive gastric cancer patients, driving a biomarker-driven strategy for breast cancer expansion.
- **$2-4B Market Opportunity**: 20,000 addressable breast cancer patients with CD47-high/HER2-positive status, targeting post-ENHERTU relapse.
- **ALX2004 Milestone**: First patient dosing in Q3 2023, with safety data expected mid-2024.
- **Extended Cash Runway**: $270M+ cash to Q1 2027, supporting key programs without dilution.

**【CEO Opening Remarks】**
- Announced new data from the ASPEN-06 trial showing CD47 expression as a predictive biomarker for evorpacept efficacy in HER2-positive gastric cancer.
- Highlighted the potential to expand evorpacept into breast cancer and other CD47-overexpressing tumor types.
- Updated guidance on extended cash runway to Q1 2027, enabling focus on key programs (evorpacept in breast cancer and ALX2004).

**【CMO Clinical Update】**
- In ASPEN-06, CD47-high patients achieved 65% ORR vs. 26% in the control arm (p < 0.05), with durable responses across DOR, PFS, and OS.
- Amended Phase II breast cancer trial to prioritize CD47-high/HER2-positive patients, with interim data expected Q3 2026.
- Preclinical data shows CD47 upregulation in HER2-positive breast cancer post-ENHERTU treatment, supporting biomarker-driven strategy.

**【CFO Financial Update】**
- Extended cash runway to Q1 2027 by halting the evorpacept colon cancer program and optimizing clinical trial spend.
- ALX2004 on track to dose first patient in Q3 2023, with initial safety data expected H1 2024.
- Focus on high-value data milestones, including CD47 biomarker validation and ALX2004 proof-of-concept.

**【Q&A Highlights】**
- FDA has approved the amended ASPEN-Breast trial protocol, with no regulatory barriers to implementation.
- Clinicians express enthusiasm for CD47 biomarker strategy, citing unmet need in post-ENHERTU breast cancer.
- Interim data from ASPEN-Breast will focus on response rates ≥40%, with durability as a secondary endpoint.
- CD47 cutoff thresholds will be determined post hoc based on ASPEN-06 data, with no prespecified value in the breast trial.

Actual	-0.5158	-0.36	-0.5	-0.35	-0.4	-0.61	-0.7	-0.6	-0.81	-0.87	-0.75	-0.74	-0.84	-1.24	-0.93	-0.71	-0.76	-0.58	-0.55	-0.58	-0.49	-0.41	-0.42
Forecast	-0.3205	-0.346	-0.3467	-0.4112	-0.4365	-0.4758	-0.6116	-0.7122	-0.6336	-0.7733	-0.8863	-0.8026	-0.88	-0.852	-0.8767	-0.8172	-0.7483	-0.78	-0.67	-0.4638	-0.422	-0.3667	-0.4
Surprise	-60.94%	-4.05%	-44.22%	+14.88%	+8.36%	-28.21%	-14.45%	+15.75%	-27.84%	-12.50%	+15.38%	+7.80%	+4.55%	-45.54%	-6.08%	+13.12%	-1.56%	+25.64%	+17.91%	-25.05%	-16.11%	-11.81%	-5.00%

Actual	527.00K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	550.00K	250.00K	-36.40K	131.00K	105.40K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	-4.18%	-100.00%	+100.00%	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

ALXO

ALXO fundamentals

ALXO Q4 2025 Earnings

Earnings Call

You can ask Aime

ALXO

ALXO fundamentals

ALXO Q4 2025 Earnings

Earnings Call

ALXO Earnings Call Summary for Q4/20258:30 AM on Feb 27, 2026

ALXO Earnings Call Summary for Q3/20258:30 AM on Nov 7, 2025

ALXO Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

ALXO Earnings Call Summary for Q1/20257:00 AM on May 8, 2025

ALXO Earnings Call Summary for Q4/2024 Apr 7, 2026

You can ask Aime